REFERENCES

1. Zeng Q, Zou D, Zeng Q, Chen X, Wei Y, Guo R. Association between insulin-like growth factor-1 rs35767 polymorphism and type 2 diabetes mellitus susceptibility: a meta-analysis. Front Genet. 2021;12:774489.

2. Kwak SH, Park KS. Recent progress in genetic and epigenetic research on type 2 diabetes. Exp Mol Med. 2016;48:e220.

3. Wang J, Zhang R, Wu C, Wang L, Liu P, Li P. Exploring potential targets for natural product therapy of DN: the role of SUMOylation. Front Pharmacol. 2024;15:1432724.

4. Zhou Y, Wu Q, Wang X, Li W, Liu Q, Gao K. Insights into the functional mechanism of diabetic kidney disease treatment with sinensetin based on network pharmacology and molecular docking. Integr Med Nephrol Androl. 2023;10:e00033.

5. Zhou S, Su L, Xu R, et al. Statin initiation and risk of incident kidney disease in patients with diabetes. Can Med Assoc J. 2023;195:E729-38.

6. Deng Y, Zhu H, Xing J, et al. The role of natural products in improving lipid metabolism disorder-induced mitochondrial dysfunction of diabetic kidney disease. Front Physiol. 2025;16:1624077.

7. Luan ZL, Zhang C, Ming WH, Huang YZ, Guan YF, Zhang XY. Nuclear receptors in renal health and disease. EBioMedicine. 2022;76:103855.

8. Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. Steroids. 2014;86:62-8.

9. Jiang T, Wang XX, Scherzer P, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes. 2007;56:2485-93.

10. Liu P, Shen Z, Wang C, Wang J, Qiu X, Li P. Tangshen formula ameliorates renal fibrosis of diabetic kidney disease through regulating the FXR/vimentin/α-SMA pathway. J Beijing University Traditional Chinese Med. 2022;45:1196-204.

11. Ma L, Yan M, Kong X, et al. Association of EPHX2 R287Q polymorphism with diabetic nephropathy in Chinese type 2 diabetic patients. J Diabetes Res. 2018:2786470.

12. Zhao H, Ma L, Yan M, et al. Association between MYH9 and APOL1 gene polymorphisms and the risk of diabetic kidney disease in patients with type 2 diabetes in a Chinese Han population. J Diabetes Res. 2018:5068578.

13. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320-3.

14. Imamura M, Maeda S. Genetics of type 2 diabetes: the GWAS era and future perspectives [Review]. Endocr J. 2011;58:723-39.

15. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007;117:2155-63.

16. Mahajan A, Wessel J, Willems SM, et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet. 2018;50:559-71.

17. Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008;40:638-45.

18. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76-80.

19. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889-94.

20. Hu M, Lui SS, Tam LS, Li EK, Tomlinson B. The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin. J Lipid Res. 2012;53:1384-9.

21. Wang XX, Wang D, Luo Y, et al. FXR/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity. J Am Soc Nephrol. 2018;29:118-37.

22. Heni M, Wagner R, Ketterer C, et al. Genetic variation in NR1H4 encoding the bile acid receptor FXR determines fasting glucose and free fatty acid levels in humans. J Clin Endocrinol Metab. 2013;98:E1224-9.

23. Fang Y, Qin M, Zheng Q, et al. Role of bile acid receptors in the development and function of diabetic nephropathy. Kidney Int Rep. 2024;9:3116-33.

24. Wang J, Liu F, Kong R, Han X. Association between globulin and diabetic nephropathy in Type2 diabetes mellitus patients: a cross-sectional study. Front Endocrinol. 2022;13:890273.

25. Hu Y, Du X. [Blood lipid indicators and different clinical classifications of dyslipidemia and diabetic kidney disease: correlation and predictive value]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023;54:1013-8.

26. Tralongo AC, Caspani F, Proserpio I, Volpi L, Campiotti L. Body mass index (BMI) influence on Cetuximab-induced antibody-dependent cellular cytotoxicity in advanced colon cancer. Intern Emerg Med. 2023;18:297-303.

27. Beaney T, Kerr GK, Kiru G, et al. May measurement month 2022: results from the global blood pressure screening campaign. BMJ Glob Health. 2024;9:e016557.

28. Delanaye P, Cavalier E, Pottel H, Stehlé T. New and old GFR equations: a European perspective. Clin Kidney J. 2023;16:1375-83.

29. Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79:268-88.e1.